Drug Type Trispecific T-cell engager (TriTE) |
Synonyms PIT565 |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD2 agonists(T-cell surface antigen CD2 agonists), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Systemic Lupus Erythematosus | Phase 1 | - | 09 Oct 2024 | |
B-Cell Lymphoma | Phase 1 | US | 03 Oct 2022 | |
B-Cell Lymphoma | Phase 1 | JP | 03 Oct 2022 | |
B-Cell Lymphoma | Phase 1 | BE | 03 Oct 2022 | |
B-Cell Lymphoma | Phase 1 | FR | 03 Oct 2022 | |
B-Cell Lymphoma | Phase 1 | IL | 03 Oct 2022 | |
B-Cell Lymphoma | Phase 1 | IT | 03 Oct 2022 | |
B-Cell Lymphoma | Phase 1 | SG | 03 Oct 2022 | |
B-Cell Lymphoma | Phase 1 | ES | 03 Oct 2022 | |
Pre B-cell acute lymphoblastic leukemia | Phase 1 | US | 03 Oct 2022 |